ACADIA Pharmaceuticals Inc. (ACAD) Social Stream
Acadia Pharmaceuticals Inc (ACAD) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Acadia Pharmaceuticals Inc.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-10 | 17 | $35 | $18 | $25.125 | $25.56 | -1.7% |
| 2021-12-07 | 17 | $35 | $18 | $25.562 | $25.56 | 0.01% |
| 2021-12-08 | 18 | $35 | $18 | $26.562 | $25.56 | 3.92% |
| 2021-12-09 | 18 | $39 | $18 | $27.235 | $25.56 | 6.55% |
| 2021-12-21 | 18 | $39 | $18 | $27.588 | $25.56 | 7.93% |
| 2021-12-22 | 19 | $42 | $18 | $28.777 | $25.56 | 12.59% |
| 2022-01-28 | 19 | $42 | $18 | $28.944 | $25.56 | 13.24% |
| 2022-02-09 | 19 | $42 | $20 | $29.944 | $25.56 | 17.15% |
| 2022-03-02 | 19 | $42 | $20 | $29.777 | $25.56 | 16.5% |
| 2022-03-10 | 19 | $42 | $20 | $30.055 | $25.56 | 17.59% |
| 2022-03-18 | 19 | $42 | $20 | $30.111 | $25.56 | 17.81% |
The Trend in the Analyst Price Target
Over the past 14 months, ACAD's average price target has gone down $31.73.
ACAD reports an average of 29.62% for its upside potential over the past 49 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-07-17 | 20 | 40 | 18 | 27.210 | 23.50 | 15.79% |
| 2021-08-14 | 20 | 35 | 18 | 25.530 | 17.58 | 45.22% |
| 2021-11-10 | 17 | 35 | 18 | 25.125 | 20.34 | 23.53% |
| 2021-12-22 | 19 | 42 | 18 | 28.777 | 23.92 | 20.31% |
| 2022-01-23 | 19 | 42 | 18 | 28.944 | 21.18 | 36.66% |
ACAD Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 2.11 | 8 | 1 | 10 | 0 | 0 | 19 |
The Trend in the Broker Recommendations
ACAD's average broker recommendation rating worsened by 0.83 over the prior 24 months.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- ACAD has a higher number of analysts covering the stock than 1122.22% of all US stocks.
- In terms of how Acadia Pharmaceuticals Inc fares relative to Pharmaceutical Products stocks, note that its upside potential (average analyst target price relative to current price) is higher than 79.01% of that group.
- In terms of how Acadia Pharmaceuticals Inc fares relative to stocks in the mid market cap category, note that its variance in analysts' estimates is lower than -894.53% of that group.
- Acadia Pharmaceuticals Inc's average analyst price target is greater than 391.68% of stocks in the mid market cap category.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Acadia Pharmaceuticals Inc are XTNT, XFOR, and VYGR.
What is the outlook for ACAD? Use POWR Ratings for clearer insight into price direction.